Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer
| Autor: | Marliese Alexander, Karishma Simadri, Arti Thakerar, Sonia Fullerton |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Pharmacological treatment 03 medical and health sciences 0302 clinical medicine Quality of life Neoplasms Internal medicine medicine Persistent cough Humans Pharmacology (medical) In patient 030212 general & internal medicine Aged Retrospective Studies Aged 80 and over business.industry Australia Cancer Middle Aged medicine.disease Advanced cancer Paroxetine respiratory tract diseases Cough 030228 respiratory system Oncology Quality of Life Female business medicine.drug |
| Zdroj: | Journal of Oncology Pharmacy Practice. 26:803-808 |
| ISSN: | 1477-092X 1078-1552 |
| DOI: | 10.1177/1078155219870594 |
| Popis: | Introduction Intractable and persistent cough is experienced by more than a third of patients with advanced cancer, with a significant negative impact on quality of life. Pharmacological treatment has been of little help in some patients. Limited evidence suggests novel agents such as paroxetine may reduce cough severity. This retrospective study aimed to assess effectiveness and tolerability of paroxetine for the treatment of intractable cough in patients with cancer. Methods Single-centre medical record review of paroxetine use in patients with advanced malignancy and cough treated at an Australia tertiary referral cancer centre between 1 October 2012 and 1 October 2017. Data relating to cough type and severity, response and adverse events were extracted from medical records. Cough type was described as non-productive dry cough, productive chesty cough or cough exhibiting both non-productive and productive features (mixed cough). Results Overall, 24/34 patients (71%) experienced a major or moderate reduction in their cough severity after treatment with paroxetine. Nearly half (47%) described a major improvement and a quarter (24%) moderate improvement. Of the 34 patients, nearly half had a lung primary cancer (16/34, 47%) and nearly all (17/18) of those without lung cancer had lung metastases from another primary cancer. Patients with dry cough reported greater benefit from paroxetine. Of the 56% (19/34) of patients with non-productive dry cough, 80% (15/19) reported an improvement in symptoms post paroxetine. The remaining 15 patients, 44% of the group, presented with either a productive chesty cough (9/34, 27%) or mixed cough (6/34, 18%). Of these patients, 60% (9/15) reported an improvement in symptoms. Two thirds of patients were commenced on paroxetine 10 mg (22/34, 65%), with the remainder starting at 20 mg (14/34, 35%). Conclusion Paroxetine may be an effective, novel, off-label treatment for intractable and persistent cough in patients with advanced cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|